Navigation Links
YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387
Date:12/6/2010

ORLANDO, FL, Dec. 6 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM) today announced positive interim data from the first 60 patients enrolled in the Phase I/II trial for its JAK1/JAK2 inhibitor, CYT387, in myelofibrosis. The results were reported today in an oral presentation at the 52nd American Society of Hematology (ASH) Annual Meeting being held in Orlando, Florida.

"Anemia is the most serious symptom associated with myelofibrosis, so I am highly encouraged by the emerging activity profile of CYT387, which uniquely continues to demonstrate a substantial ability to improve anemia while producing similar results to its peers in reducing spleen size and controlling constitutional symptoms," noted Dr. Alayew Tefferi, Chair of the Study. "I also encourage YM to evaluate CYT387 in other diseases where anemia has a significant impact."

"These unprecedented results highlight the potential safety and efficacy advantages of CYT387 compared with other JAK inhibitors. If CYT387 continues to demonstrate this unique anemia benefit in larger trials, it may ultimately serve as a drug of choice for the majority of patients with myelofibrosis who find anemia problematic," said Dr. Nick Glover, President and CEO of YM BioSciences. "We look forward to updated data from the full 140 patient trial in calendar mid-2011."

Patient Characteristics:

The presentation described interim results for the first 60 patients enrolled in the dose escalation (n=21) and dose confirmation (n=39) portions of the 140 patient Phase I/II trial, for which recruitment is ongoing. In the dose-confirmation phase, subjects were started at one of two dose levels that were deemed clinically effective: 150 mg/day (n=18) and 300 mg/day (n=21). Thirty-three subjects (55%) were red cell transfusion-dependent at study entry. Forty-five subjects (75%) expressed the JAK2V617F mutation.
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387
2. Ardea Biosciences to Present at Two Upcoming Investor Conferences
3. YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results
4. YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS
5. Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
6. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
7. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
8. X-BODY BioSciences Awarded Grant for Therapeutic Discovery Project Targeting Metastatic Tumor Stem Cells
9. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
10. Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
11. GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... CA (PRWEB) January 15, 2014 ... research solutions, today announced that Lupin Limited, one of ... Freeslate’s CM Protégé PharmD System for high ... Mumbai, India, is focused on a wide range of ...
(Date:1/14/2014)... 2014 Date: Friday, April 11, 2014 , ... Club, 1360 Almshouse Road, Warrington, Pa. , Details: ... dedicated to finding a cure for hepatitis B and improving ... its annual Crystal Ball on Friday, April 11 at Warrington ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of ... regulatory, business, and media events in the United States ... former associate Virginia Cox , JD, is returning to the ... Virginia Cox re-joins 3D after more than two years of ...
(Date:1/14/2014)... The largest international professional organization of scientists ... derivatives thereof has endorsed an educational program that ... challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural Product ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8
... Fisher,Scientific Inc. (NYSE: TMO ) today ... a leading third-party logistics provider to the,pharmaceutical ... was previously majority-owned by Arsenal Capital,Partners. With ... Priority,Solutions offers a comprehensive range of services ...
... With a special eye for the,details hidden from casual ... G. Aspinall. Photographs of architectural details from beaches,to buildings ... fore. The,collection includes images from seven different countries., ... the,president of Genzyme Genetics, is also a talented artist ...
... - Biomira Inc. (Nasdaq: BIOM ),(TSX: BRA) ... Chief,Executive Officer, is scheduled to present at the ... EDT on Wednesday, October 10. The presentation ... be accessed at: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=BIOM&item_id=1 ,657575 ...
Cached Biology Technology:Thermo Fisher Scientific Acquires Logistics Provider to Strengthen Clinical Trials Management Services 2Thermo Fisher Scientific Acquires Logistics Provider to Strengthen Clinical Trials Management Services 3Thermo Fisher Scientific Acquires Logistics Provider to Strengthen Clinical Trials Management Services 4An Uncommon Eye: Photography Exhibit by Biotechnology Executive at BHCC Gallery 2
(Date:4/23/2014)... are turning away from using triclosan as an antimicrobial ... concerns. And now scientists are reporting new evidence that ... the ACS journal Chemical Research in Toxicology , ... called octylphenol, promoted the growth of human breast cancer ... mice. , Kyung-Chul Choi and colleagues note that hormonal ...
(Date:4/23/2014)... first cause of dementia and affects some 400,000 people ... been found. One of the reasons for this is ... cause alterations in nerve transmissions and the loss of ... from the Institute of Neuroscience at the Universitat Autnoma ... memory consolidation and were able to develop a gene ...
(Date:4/23/2014)... technique used to read quickly. It involves visual ... words and/ or sentences. Similarly to humans, biological ... "read" genetic information. Genes that need to be ... the encoding message, the easier it will be ... Gulbenkian de Cincia (IGC, Portugal) and Centre for ...
Breaking Biology News(10 mins):In lab tests, the antimicrobial ingredient triclosan spurs growth of breast cancer cells 2Loss of memory in Alzheimer's mice models reversed through gene therapy 2Cell division speed influences gene architecture 2
... Inc., (formerly Automated Vending Technologies) (Ticker: AVTCD.PK) ( ... automated retailing industries by offering an ATM-style kiosk ... 24-hours a day, without the need for a ... system uses advanced biometric fingerprint recognition and a ...
... University Medical Center researchers have found a genetic variant ... after a coronary artery bypass. The scientists ... two different sets of patients, with about 1,000 patients ... "After the second analysis, we were ecstatic to see ...
... September 13, 2011 New research conducted at the ... a healthy liver. The pilot study, conducted by Dr. Keiko ... and Life Sciences, showed that healthy laboratory rats fed a ... pure maple syrup from Canada yielded significantly better results in ...
Cached Biology News:Gene linked with death after coronary bypass surgery 2Researchers uncover a potential new benefit of pure maple syrup on liver health 2
LECHNER AND LaVECK MEDIUMfor the clonal growth of normal human bronchial and other epithelial cells. Requires additives. With glutamine.Recommended storage condition:oC to 8oCIntended use(s):research...
...
... OrientExpress™ System Modules ... synthesis and directional cloning ... T7 expression vectors ... configuring OrientExpress™ Cloning Systems, ...
... and antibody-based immunoaffinity matrices, such as ... times without compromising antigen-antibody reactivity, the ... agents has precluded the application of ... The CHEMICON Re-Blot Plus Western Blot ...
Biology Products: